Vir Biotechnology Inc (VIR)

Jun 17, 2025

Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com

Jun 17, 2025

Jun 10, 2025

Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener

Jun 10, 2025

Jun 05, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Jun 05, 2025

Jun 03, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia

Jun 03, 2025

Jun 02, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com Nigeria

Jun 02, 2025

May 29, 2025

Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks

May 29, 2025

May 29, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace

May 29, 2025

May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus

May 28, 2025

May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus

May 28, 2025

May 27, 2025

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com

May 27, 2025

May 22, 2025

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 22, 2025

May 22, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus

May 22, 2025

May 21, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace

May 21, 2025

May 20, 2025

Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia

May 20, 2025

May 20, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus

May 20, 2025

May 20, 2025

Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia

May 20, 2025

May 20, 2025

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

May 20, 2025

May 20, 2025

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025

May 15, 2025

How To Trade (VIR) - news.stocktradersdaily.com

May 15, 2025

May 15, 2025

Vir announces 24-week post-end of treatment data for Hep B therapy - MSN

May 15, 2025

May 14, 2025

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

May 14, 2025

May 12, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus

May 12, 2025

May 12, 2025

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace

May 12, 2025

May 12, 2025

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

May 12, 2025

May 12, 2025

Vir Biotechnology Announces Results of Its Potential Hepatitis B Cure Combination Therapy - ContagionLive

May 12, 2025

May 11, 2025

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

May 11, 2025

May 10, 2025

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

May 10, 2025

May 10, 2025

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

May 10, 2025

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus

May 09, 2025

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace

May 09, 2025

May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus

May 09, 2025

May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

May 09, 2025

May 09, 2025

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

May 09, 2025

May 09, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025

May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025

May 09, 2025

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

May 09, 2025

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

May 09, 2025

May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025

May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025